Efthimiou J, Higenbottam T, Holt D, Cochrane G M
Thorax. 1982 Jan;37(1):68-71. doi: 10.1136/thx.37.1.68.
Peak plasma concentrations of lignocaine were recorded in 41 patients receiving topically applied lignocaine for fiberoptic bronchoscopy. Adequate anaesthesia was achieved in all patients with an average dose per unit weight of 9.3 +/- 0.5 mg/kg (SEM) giving a mean peak plasma concentration of 2.9 +/- 0.5 mg/l-1 (SEM) (+/- SEM 0.5). The plasma concentration exceeded toxic levels of 5.0 mg/l-1 in only two patients, and no complications were observed. Peak concentrations were influenced only by dose per unit weight administered and not by factors considered likely to influence mucosal absorption from the bronchial tree, such as sputum production, airflow obstruction, or cigarette smoking. A major proportion of the total dose of lignocaine was required to anaesthetise the nose, pharynx, and larynx, only a small proportion being needed for the bronchial tree. Lignocaine gel (2% w/v) was preferred by patients, and in a study of 10 volunteers, produced lower plasma concentrations when used as a topical anaesthetic than did lignocaine aerosol (10% w/v) or lignocaine solution (4% w/v).
在41例接受局部应用利多卡因进行纤维支气管镜检查的患者中记录了利多卡因的血浆峰值浓度。所有患者均实现了充分麻醉,单位体重平均剂量为9.3±0.5mg/kg(标准误),平均血浆峰值浓度为2.9±0.5mg/l-1(标准误)(±标准误0.5)。仅2例患者的血浆浓度超过了5.0mg/l-1的中毒水平,且未观察到并发症。峰值浓度仅受给药的单位体重剂量影响,而不受那些被认为可能影响从支气管树黏膜吸收的因素影响,如痰液产生、气流阻塞或吸烟。麻醉鼻子、咽部和喉部需要利多卡因总剂量的一大部分,支气管树只需一小部分。患者更喜欢利多卡因凝胶(2%w/v),在一项对10名志愿者的研究中,用作局部麻醉剂时,其产生的血浆浓度低于利多卡因气雾剂(10%w/v)或利多卡因溶液(4%w/v)。